Climb Bio CLYM
NASDAQ CLYM
$15.52 +0.93 (+6.37%)
As of: Sep 4, 2026 · 3:59 PM EDT

Climb Bio (CLYM) Non-Current Deferred Tax Liability (2021 - 2025)

Climb Bio's (CLYM) quarterly Non-Current Deferred Tax Liability came in at $91000.0 in Q4 2025, down 34.06% YoY from $138000.0 in Q4 2024, and down 34.06% on a QoQ basis from $138000.0 in Q4 2024.

Analysis

Climb Bio (CLYM) Non-Current Deferred Tax Liability (2021 - 2025) Analysis & Trends

Climb Bio (CLYM) has 3 years of Non-Current Deferred Tax Liability data on file, last reported at $91000.0 in Q4 2025.

  • Quarterly Non-Current Deferred Tax Liability fell 34.06% year-over-year to $91000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $91000.0 (down 34.06% YoY) and the FY2025 annual result came in at $91000.0, down 34.06% from the prior year.
  • Non-Current Deferred Tax Liability retreated to $91000.0 in Q4 2025, from $138000.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $138000.0 in Q4 2024 to a low of -$11000.0 in Q4 2021.
  • A 3-year average of $72666.7 and a median of $91000.0 in 2025 frame the typical range for Non-Current Deferred Tax Liability.
  • The widest YoY moves for Non-Current Deferred Tax Liability: up 34.06% in 2025, down 34.06% in 2025.
  • Tracing CLYM's Non-Current Deferred Tax Liability over 3 years: stood at -$11000.0 in 2021, then jumped by 1354.55% to $138000.0 in 2024, then tumbled by 34.06% to $91000.0 in 2025.
  • The last three Non-Current Deferred Tax Liability figures came in at $91000.0 (Q4 2025), $138000.0 (Q4 2024), and -$11000.0 (Q4 2021), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Climb Bio 1.18 Bn 1.18 Bn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 91,000.00
Dec 31, 2024 138,000.00
Dec 31, 2021 -11,000.00